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Plants are increasingly being used for the production of recombinant proteins. One reason
is that plants are highly amenable to glycan engineering processes and allow the production
of therapeutic proteins with increased efﬁcacies due to optimized glycosylation proﬁles.
Removal and insertion of glycosylation reactions by knock-out/knock-down approaches and
introduction of glycosylation enzymes have paved the way for the humanization of the plant
glycosylation pathway.The insertion of heterologous enzymes at exactly the right stage of
the existing glycosylation pathway has turned out to be of utmost importance. To enable
such precise targeting chimeric enzymes have been constructed. In this short review we
will exemplify the importance of correct targeting of glycosyltransferases, we will give an
overview of the targeting mechanism of glycosyltransferases, describe chimeric enzymes
used in plant N -glycosylation engineering and illustrate how plant glycoengineering builds
on the tools offered by synthetic biology to construct such chimeric enzymes.
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INTRODUCTION
The medicinal use of proteins and blood products has a long
history. Already in the 15th century ailing pope Innocent VIII
was reportedly infused with blood from three healthy boys to give
him back vigor and strength, however, with a fatal outcome for all
four of them (Rivera et al., 2005). The ﬁrst successful blood trans-
fusion was made in 1665 between dogs (Felts, 2000) and it took
over 150 years for the ﬁrst successful transfusion between humans
(Blundell, 1818). Proteins puriﬁed from animal or human tis-
sues (growth hormones, insulin, clotting factors, or other blood
components) have been used for medicinal purposes since the
beginning of the 20th century (e.g., Eibl, 2008; Blizzard, 2012)
and with the advent of recombinant protein production possibil-
ities, many of those proteins are now produced recombinantly.
The market for pharmaceutical proteins is assumed to currently
amount to roughly 150–200 billion US$, and develops strongly
with growth rates of ∼10% and more (Walsh, 2010; Elvin et al.,
2013;Aggarwal,2014). Special drivers of this growth are antibodies
and antibody related products, but also other types of proteins are
selling well, like insulin, vaccines, erythropoietin, etc. (Aggarwal,
2014).
A current major concern in producing biopharmaceuticals is
a special type of post-translation modiﬁcation (PTM), namely
N-glycosylation. This PTM is found on a large proportion of
pharmaceutically relevant proteins (Walsh, 2010) and can inﬂu-
ence protein characteristics like folding and assembly, solubility
and charge, serum half-life, functionality, etc. (e.g., Varki, 1993;
Roth et al., 2010; Solá andGriebenow, 2010). As different cell types
attach different glycans, the characteristics of the N-glycosylated
protein can be strongly affected by the expression host – a fact
that should be considered carefully when choosing the production
system. For example, bacteria generally do not glycosylate proteins
and yeasts attach larger glycan structures than mammals. Insect
cells decorate proteins with paucimannosidic N-glycans which are
normally not present in humans. Plants produce complex type
N-glycans similar to humans, however, certain non-mammalian
epitopes are attached and more complex human-type glycosyla-
tion cannot be produced (for reviews on typcial N-glycosylation
patterns and glycoengineering of different expression hosts see,
e.g., Jacobs and Callewaert, 2009; Loos and Steinkellner, 2012).
Another concern is glycan microheterogeneity, i.e., attachment of
different N-glycans to the same N-glycosylation site, as homo-
geneously glycosylated products are required by the regulatory
authorities. Thus, research has focused on modifying the glyco-
sylation characteristics of a variety of expression systems to allow
homogeneous, human-type N-glycosylation (Umana et al., 1999;
Yamane-Ohnuki et al., 2004; Schuster et al., 2005; Cox et al., 2006;
Li et al., 2006; Strasser et al., 2009; Pandhal and Wright, 2010;
Meuris et al., 2014) and resulted in the production of proteins
carrying modiﬁed glycans and often showing improved in vivo
functions.
Plants have proven their capability regarding production speed,
ease of scale up and to meet quality standards demanded
by regulatory agencies for clinical applications (Gleba et al.,
2014; Stoger et al., 2014). Also governmental agencies like the
Defense Advanced Research Projects Agency [DARPA] (2012)
have recognized the advantages of this technology for the quick
manufacturing of vaccines, difﬁcult to produce biopharmaceu-
ticals, etc. This has led to massive investments in research,
production facilities complying with current quality standards
(Defense Advanced Research Projects Agency [DARPA], 2012;
www.federalgrants.com, 2012; Stoger et al., 2014) and the ﬁrst
products on the market. Glucocerebrosidase, an enzyme to
treat Gaucher’s disease, has been approved by the FDA in
2013 as the ﬁrst plant-produced, parenterally applied bio-
pharmaceutical (Zimran et al., 2011; van Dussen et al., 2013).
Additionally, several plant-made pharmaceuticals have received
approval for clinical trials and other plant-produced products are
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already marketed as research/diagnostic reagent, medical device,
cosmetic product etc. (recently reviewed by Gleba et al., 2014;
Goodman, 2014; Stoger et al., 2014). Many of these proteins are
glycosylated.
In this review we will discuss the approaches taken to engineer
the N-glycosylation pathway in Nicotiana benthamiana and put
a strong focus on recently developed and applied semi-synthetic
strategies using chimeric glycosyltransferases.
PLANT GLYCOSYLATION
In plants as in other eukaryotes, the endoplasmic reticulum (ER)
and the Golgi apparatus play the central role in protein glyco-
sylation and contain the majority of glycan modifying enzymes
(reviewed by, e.g., Helenius and Aebi, 2001). While the ER and
its glycan processing repertoire are largely conserved between
phyla (and kingdoms), morphology and function of the Golgi
differ to some extent (Loos and Steinkellner, 2012; Aebi, 2013).
For example, a main function of the plant but not the mam-
malian Golgi is to provide large amounts of polysaccharides, a
fundamental component of the cell wall (Oikawa et al., 2013).
Early N-glycosylation steps that take place in ER and cis-Golgi
are virtually identical in higher eukaryotes, while further pro-
cessing differs (recently reviewd by, e.g., Loos and Steinkellner,
2012; Bosch et al., 2013). This is mainly due to a drastically
reduced repertoire of glycosylation enzymes in plants, where
a small number of Golgi-located N-glycan processing enzymes
gives rise to typically two different glycan structures (Castilho
and Steinkellner, 2012). By comparison, over 2000 different N-
glycans have been described on mammalian proteins which arise
from several 100 enzymes in the secretory pathway (Campbell
and Yarema, 2005; Ohtsubo and Marth, 2006; Varki, 2006).
Notwithstanding these differences, the Golgi of higher eukary-
otes shares a remarkably high degree of homology, especially
with respect to organization, proteome, and N-glycosylation
capabilities.
Plant proteins typically carry two major N-glycans, complex
GnGnXF and paucimannosidic MMXF (Strasser et al., 2004a,
2007a; for glycan nomenclature see http://www.proglycan.com/
upload/nomen_2007.pdf). These two glycans contain core α1,3-
fucose and β1,2-xylose which are plant-speciﬁc glyco-epitopes.
They are not produced by mammalian cells and up to 50% of
humans have been shown to carry substantial amounts of anti-
bodies directed against these epitopes in their blood (Bardor
et al., 2003). The abundantly present paucimannosidic structures
(MMXF, truncated glycans lacking terminal GlcNAc residues;
Dirnberger et al., 2001; Strasser et al., 2007a; Liebminger et al.,
2011) are also a plant peculiarity, otherwise only found in
insect cells (Altmann et al., 1999, 2001). In some cases plant
proteins carry so-called Lewis A epitopes, terminally β1,3-
galactosylated and α1,4-fucosylated structures (Fitchette-Laine
et al., 1997; Strasser et al., 2007b). The abundance of this epi-
tope differs strongly between species (Fitchette et al., 1999; Wilson
et al., 2001) and organs (Strasser et al., 2007b), but seems low in
Arabidopsis and Nicotiana (Fitchette et al., 1999; Strasser et al.,
2007b, 2008; Matsuo and Matsumura, 2011). Noteworthy is also
the absence of core α1,6-fucosylation in plants, a glycan residue
present on the vast majority of proteins produced in mammalian
cells. Removal of this residue from immunoglobulin G (IgG) gly-
cans increases functional activities of antibodies due to a higher
afﬁnity to the antibody-dependent cell-mediated cytotoxicity
(ADCC) inducing IgG receptor FcγRIIIa (Shinkawa et al., 2003;
Jefferis, 2009).
The limited glycosylation capacity of plants has turned out to
be an advantage for the generation of proteins that need homo-
geneous glycosylation. For example, IgG antibodies produced
in plants carry usually 1–2 different glycan structures (mainly
GnGnXF) while the same antibodies produced in Chinese hamster
ovary (CHO) cells bear 5–7 structures (Strasser et al., 2008, 2009).
For some applications, like testing of functional activities, and
according to the demands from regulatory agencies, homogeneous
glycosylation is required.
Plants display a remarkable tolerance toward the manipula-
tion of their intrinsic glycan biosynthetic pathways. Elimination
of complex glycans, knock-out of plant-speciﬁc xylosyl- and
fucosyltransferases (XT and FT) or reduction/overproduction of
the Lewis A epitope did not lead to any obvious phenotype
in Arabidopsis thaliana under standard growth conditions (Von
Schaewen et al., 1993; Strasser et al., 2004b, 2007b). Also Lemna
minor and N. benthamiana, one of the major plant-based pro-
tein production platforms, tolerate a variety of glycoengineering
steps without obvious phenotypes or impact on development
(Cox et al., 2006; Strasser et al., 2008; Nagels et al., 2011). Only
few cases of sensitive reactions to glycosylation changes have
been described (Fanata et al., 2013). This general tolerance for
glycoengineering was a prerequisite for humanizing the plant
N-glycosylation pathway. A combination of knock-out/knock-
down and knock-in approaches together with transient expression
techniques has allowed the removal of potentially immuno-
genic residues, and the addition of new, human-type glyco-
structures. Modular, semi-synthetic constructs assembled on
multi-gene vectors enable the efﬁcient manipulation of the glyco-
sylation pathway. These glycoengineering strategies are addressed
below.
PLANT GLYCOENGINEERING
Engineering of plant glycans toward human structures requires
two main types of modiﬁcation: (i) plant-speciﬁc reactions have
to be eliminated and (ii) reactions taking place in humans but
not in plants have to be introduced. Reducing the unwanted
plant-speciﬁc modiﬁcations, i.e., β1,2-xylosylation and core
α1,3-fucosylation, has initially been achieved by targeting the
recombinant protein to the ER or co-overexpressing glycosy-
lation enzymes competing for the same substrate (e.g., Palac-
pac et al., 1999; Bakker et al., 2006; Frey et al., 2009; Vézina
et al., 2009; Karg et al., 2010; see below). However, as these
approaches interfere with the execution of endogenous glycosy-
lation processes and cause the attachment of oligomannosidic
or incompletely processed and aberrant glycans they are only
of limited use. RNAi approaches targeting the transcript of the
unwanted glycosyltransferases or complete knock-outs by T-DNA
insertion have proven more successful (Koprivova et al., 2004;
Strasser et al., 2004b, 2008; Cox et al., 2006; Sourrouille et al.,
2008; Shin et al., 2011; Parsons et al., 2012). Importantly, such
plants produce human-type GnGn glycans, which serve as an
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acceptor substrate for further mammalian modiﬁcations and
were thus important milestones in the engineering of the plant
N-glycosylation pathway toward the production of human-type
structures.
Consequently, work over the past decade on the controlled
expression of mammalian glycosyltransferases has established
plant-based systems that synthesize a series of deﬁned human-
type glycan structures (Castilho et al., 2012; recently reviewed
by Bosch et al., 2013). Recent studies demonstrate how even
entire glycosylation-associatedbiosynthetic pathways canbe intro-
duced. Plants do not have the machinery to synthesize the sugar
nucleotide precursor CMP-sialic acid (CMP-N-acetylneuraminic
acid) necessary for sialylation. The simultaneous overexpression
of six mammalian genes enabled the in planta generation of acti-
vated sialic acid, the transfer of the activated sugar nucleotide
to the Golgi, the production of terminally galactosylated glycans
and the transfer of sialic acid to these terminal galactoses (see
Figures 1A–D; Castilho et al., 2008, 2010).
In planta sialylation of glycans thereby highlights some of
the reasons why simple overexpression of a mammalian gly-
cosyltransferase in plants has not always proven successful in
generating human-type glycans: acceptor as well as donor sub-
strates need to be present. For example, when Wee et al.
(1998) expressed the human α2,6-sialyltransferase in Arabidop-
sis, activity of the enzyme could only be shown after applying
donor and acceptor substrates in trans, as plants lack both.
The achievements by Palacpac et al. (1999), Bakker et al. (2006)
and others pointed out one more challenge, namely how del-
icate the glycosylation system is – coexpression of the human
β1,4-galactosyltransferase (β1,4-GalT) had led to the produc-
tion of galactosylated, but also of unusual, hybrid-type glycans.
The latter was due to activity of the galactosyltransferase at
a suboptimal stage of the glycosylation pathway and interfer-
ence with the endogenous glycosylation reactions (described in
detail below). Similar ﬁndings were reported upon overexpression
of N-acetylglucosaminyltransferase (GnT) III (Rouwendal et al.,
FIGURE 1 | N-glycoengineering in plants to produce tetra-sialylated
proteins. Schematic representation of an extensively glycoengineered
plant-produced glycoprotein (erythropoietin;A). It represents the front of
plant glycan engineering and illustrates, in short, the transformation of
glycans present in Nicotiana benthamiana wild-type plants (GnGnXF) to ﬁnally
obtain a glycosylation proﬁle present on human serum EPO (NaNaNaNa). For
such intensive N -glycoengineering, a series of individual steps are necessary
(B; 1): knock-out or knock-down of plant-speciﬁc β1,2-XT and core α1,3-FT, (2)
introduction of GnTIV and GnTV responsible for branching, (3) introduction of
β1,4-GalT, (4) introduction of sialyltransferase in combination with the
biosynthetic pathway to produce activated sialic acid (not shown). Symbols for
monosaccharides are given in (C), symbols depicting which monosaccharide
atoms are involved in the linkage are given in (D). For detailed description see
publications by Castilho et al. (2010, 2011, 2012, 2013). A more detailed
explanation of N -glycan nomenclature and graphical illustrations can be found
at http://www.proglycan.com/upload/nomen_2007.pdf
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2007; Frey et al., 2009; Karg et al., 2010; Castilho et al., 2011;
detailed description see below). These examples show that the
ﬁnal glycosylation proﬁle of a co-expression approach depends
on various factors, including the availability of (i) acceptor
glycan and (ii) donor substrate as well as (iii) the correct
subcellular targeting of the recombinant glycosyltransferase in
order to avoid interference with the endogenous glycosylation
machinery.
TARGETING MECHANISM OF GLYCOSYLTRANSFERASES
The glycosylation reactions within the Golgi are carried out in
a sequential, stepwise manner, and one reaction can be the pre-
requisite for another one – or inhibit it. Therefore, the ordered
sequential arrangement of enzymatic activities, i.e., the correct
subcellular localization of the involved enzymes is of utmost
importance. This tight regulation has consequences for the expres-
sion and targeting of heterologous glycosylation enzymes, as
they need to ﬁt precisely into the existing pathway. Fine-tuning
the subcellular localization of heterologously expressed glycosyla-
tion enzymes requires vast knowledge of the underlying targeting
mechanisms.
All known Golgi-resident N-glycosyltransferases are type II
transmembrane proteins (reviewed by, e.g., Schoberer and
Strasser, 2011). Their N-terminus is exposed to the cytoplasm,
followed by a transmembrane domain, a stem, and the catalytic
domain (see Figure 2). The cytoplasmic part, transmembrane
domain, and stem are referred to as CTS region and are responsible
FIGURE 2 | Structure of N-glycosyltransferases. Golgi-located
glycosyltransferases are type II transmembrane proteins. Their localization
within the Golgi depends on the N-terminal CTS region, consisting of the
cytosolic tail, the transmembrane domain and a stem. The C-terminal
catalytic domain is directed to the Golgi lumen.
for targeting the enzyme to the correct compartment (Essl et al.,
1999), and even sub-compartment. This was shown by different
Golgi-localized glycosyltransferases not present within the same
sub-compartment (Saint-Jore-Dupas et al., 2006; Schoberer et al.,
2009, 2010).
Research activities to elucidate the targeting mechanism(s)
of type II transmembrane proteins revealed a basic conserva-
tion of processes between plants and mammals (Schoberer et al.,
2010). However, the question on how the ﬁne-tuning of targeting
works has not been answered deﬁnitively, but several factors have
been identiﬁed. For example, the cytoplasmic tail inﬂuences ER
export of the enzyme (Schoberer et al., 2009) and can change the
ﬁnal destination of a protein (Jiang and Rogers, 1998). In mam-
malian cells it has been shown to relocate the catalytic domain
from one to another Golgi subcompartment (Uliana et al., 2006).
This might be due to formation of homo- or heterodimers of
the enzymes or interaction with other proteins (Schoberer et al.,
2013). Also the length of the transmembrane domain might inﬂu-
ence targeting (Pagny et al., 2003), as the membrane thickness of
the Golgi changes from cis to trans. Finally, the composition of
the lipid bilayer surrounding the enzyme might inﬂuence target-
ing, too (reviewed by Schoberer and Strasser, 2011). This makes
the CTS regions of glycosyltransferases key regulators for pre-
cise sub-Golgi targeting. Theoretically, CTS domains from any
eukaryotic organism may serve as a suitable targeting domain.
Recent genome sequencing projects provided an abundance of
such sequences that may be used for targeted sub-Golgi local-
ization (Ohtsubo and Marth, 2006; Varki, 2006). Nevertheless,
as the molecular mechanisms that lie behind this ﬁne-tuning of
targeting are not fully understood, it is not entirely predictable
how CTS sequences actually perform when fused to the cat-
alytic domain of another glycosyltransferase and expressed in
a foreign cell. Thus, experimental testing is required. Also the
prediction of the exact size of the individual glycosyltransferase-
domains (cytosolic tail, transmembrane domain, stem, catalytic
domain) is difﬁcult and even though bioinformatics prediction
technology has improved in recent years, different algorithms
can lead to different results. Therefore, the reliability of the
identiﬁcation of the separate domains should be considered
carefully.
CHIMERIC GLYCOSYLTRANSFERASES USED FOR IN PLANTA
GLYCOENGINEERING
First steps to shift the plant N-glycosylation pattern from plant-
speciﬁc N-glycans (i.e., GnGnXF, MMXF, etc.; see Figure 3A)
toward the production of human-like structures were based on
full-length mammalian glycosyltransferases. Expressing a human
β1,4-GalT in tobacco plants (Bakker et al., 2001) and tobacco BY2
cells (Palacpac et al., 1999) in fact resulted in galactosylated gly-
cans, however, other oligosaccharides were produced as well. In
BY2 cells, unusual and incompletely processed glycans lacking
xylose and fucose (e.g., Man5A) were abundant (see Figure 3B),
indicating interference of the heterologously expressed GalT
with endogenous glycan processing enzymes like mannosidase
II, GnTII and plant-speciﬁc β1,2-xylosyltransferase and α1,3-
fucosyltransferase (XT and FT). In tobacco plants, xylosylated,
and fucosylated GnGnXF remained the main oligosaccharide (see
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FIGURE 3 | Continued
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FIGURE 3 | Continued
Expression of β1,4-GalT and chimeric versions thereof in plants.
Schematic presentation of various β1,4-GalT constructs expressed in plants
and the consequences on the glycosylation proﬁle of total and
recombinantly expressed proteins. In the top panel β1,4-GalT catalytic
domain and various CTS regions are illustrated in different colors. The color
code is used to better visualize various chimeric fusion constructs. The
bottom panel shows a Golgi stack and the hypothetical localization of
different β1,4-GalT constructs. Green arrows indicate cargo ﬂow from ER
through the Golgi. Major glycan structures produced under the given
conditions are shown. (A) Major glycoforms detected in wild-type plants
(without the expression of β1,4-GalT) are complex N -glycans carrying xylose
and fucose (i.e., GnGnXF, MMXF, etc.; e.g., Bakker et al., 2001).
(B) Expression of full-length human β1,4-GalT in BY2 tobacco cells (Palacpac
et al., 1999) and tobacco plants (Bakker et al., 2001) led to different results.
In BY2 cells, mainly galactosylated, hybrid-type glycans (like Man5A) as well
as oligomannosidic glycans were found (Palacpac et al., 1999). In tobacco
plants (Bakker et al., 2001) GnGnXF remained the major glycoform and only
small amounts of galactosylated glycans were found. These results indicate
that β1,4-GalT acted in BY2 cells at an earlier stage of the glycosylation
pathway than in tobacco plants, leading to interference with endogenous
glycosylation reactions in cells, but not in plants. (C) Major glycoforms
detected upon expression of a chimeric GalT, that carries the CTS region of
A. thaliana β1,2-xylosyltransferase (indicated in pale green) and targets the
enzyme to a medial stage of the glycan processing pathway: Man5, ManGn,
Man5A. A drastically reduced amount of xylosylated and fucosylated
glycans was detected (Bakker et al., 2006). The results point to an early
activity of the chimeric β1,4-GalT, most probably in medial Golgi stacks.
(D)Targeting the GalT to an even earlier compartment by fusing it to the CTS
of the cis-Golgi acting GnTI (indicated in yellow; Vézina et al., 2009) induced
the production of nearly exclusively oligomannosidic structures. Only
minute amounts of galactosylated, hybrid Man5A were present. (E) Upon
expression in a XT/FT knock-down plant line of a chimeric GalT carrying the
late-Golgi CTS of rat α2,6-sialyltransferase (indicated in orange) proteins
carrying mainly galactosylated glycans (e.g., AA) were generated (Strasser
et al., 2009). These results indicate that the ST-GalT fusion is indeed located
in a late Golgi stack where ﬁnal N -glycan processing takes place.
Figure 3B) and only minor amounts of galactosylated oligosac-
charides like AAXF or GnAXF were found. This points to activity
of the GalT at a later stage in tobacco plants, after comple-
tion of the endogenous glycosylation reactions. At this later
stage, interference with the endogenous glycosylation reactions
did not take place and therefore the amount of β1,2-xylose and
α1,3-fucose – residues unwanted on proteins needed for human
applications – remained basically unchanged. In order to trans-
fer the down-regulation effect observed in BY2 cells to tobacco
plants and reduce/eliminate the two plant-speciﬁc glycan residues
(β1,2-xylose and α1,3-fucose), a chimeric version of the human
GalT was constructed that contained the CTS region of the A.
thaliana β1,2-xylosyltransferase (Bakker et al., 2006). The inten-
tion was to generate a chimeric enzyme that acts in the medial
Golgi, simultaneously or prior to the endogenously present β1,2-
xylosyltransferase and core α1,3-fucosyltransferase (XT and FT).
As β1,4-galactosylated proteins are no longer substrates for XT
and FT (Staudacher et al., 1995; Kajiura et al., 2012), the expres-
sion in tobacco plants led to the intended, drastic decrease in
plant-speciﬁc glycans. However, the early activity of the β1,4-GalT
also led to the inhibition of other enzymes – like mannosidase II
and GnTII – and thus to the generation of substantial amounts
of unusual, incompletely processed glycans (oligomannosidic gly-
cans, Man5A, etc.; see Figure 3C). Altogether, the glycan proﬁle
was similar to the proﬁle of BY2 cells expressing the full-length
human β1,4-GalT (Palacpac et al., 1999). This indicates that the
chimeric construct in tobacco plants and the full-length, human
GalT in BY2 cells show activity at a comparable stage of the
glycosylation pathway.
Targeting the human β1,4-GalT to an even earlier compart-
ment (ER/cis-Golgi) by fusion with the CTS region of the A.
thaliana GnTI further increased the amount of oligomanno-
sidic glycans (Vézina et al., 2009; see Figure 3D). Galactosy-
lated oligosaccharides were hardly found, indicating increased
interference with the glycosylation machinery and the secretory
pathway.
With the advent of XT/FT knock-down or knock-out lines
(Koprivova et al., 2004; Cox et al., 2006; Schähs et al., 2007; Strasser
et al., 2008; Shin et al., 2011) a more elegant way to prevent
plant-speciﬁc glycosylation had been established and the aim of
co-expressing human GalT in plants shifted from“interfering with
endogenous reactions” to “generating homogeneously galactosy-
lated, human-type glycans.” This was achieved by a rationally
designed construct targeting the GalT to a late Golgi compart-
ment. Fusions of the catalytic GalT domain to the CTS region
of α2,6-sialyltransferase, an enzyme acting in the ﬁnal steps of
the mammalian glycosylation pathway, indeed resulted in the gen-
eration of human-type, mono- and di-galactosylated glycans in
XT/FT knock-down plants (Strasser et al., 2009; see Figure 3E).
This was an important step for the in planta generation of proteins
carrying fully human glycans.
This semi-synthetic approach was applied to GnTs to further
explore the consequences of generating hybrid constructs carrying
foreign CTS regions. One of the GnTs, β1,4-mannosyl-β1,4-N-
acetylglucosaminyltransferase (GnTIII), catalyzes the formation
of so-called bisected glycans (Carver et al., 1981; Narasimhan,
1982), a modiﬁcation frequently found on human proteins
but not present in plants (Rouwendal et al., 2007). Impor-
tantly, bisected – as well as the previously mentioned β1,4-
galactosylated glycans – cannot be modiﬁed with plant-speciﬁc
xylose or fucose residues (Rouwendal et al., 2007). In order to
produce such bisected glycans and thus prevent the addition of
plant-speciﬁc glyco-epitopes, fully human GnTIII and a hybrid
construct (the catalytic domain was fused to the CTS region
of A. thaliana α-mannosidase II) were expressed in tobacco
plants and BY-2 tobacco cells. The chimeric constructs led to
a stronger decrease in plant-speciﬁc glyco-epitopes most prob-
ably due to targeting to an early/medial Golgi subcompartment
(Rouwendal et al., 2007; Frey et al., 2009; Karg et al., 2010).
However, targeting of GnTIII to an early compartment not
only inhibited unwanted reactions but also led to the genera-
tion of non-standard, mainly hybrid-type glycans. Transiently
expressing a series of GnTIII-constructs containing different CTS
regions (A. thaliana Golgi mannosidase II, A. thaliana core α1,3-
fucosyltransferase, A. thaliana β1,2-xyloslytransferase, and rat
α2,6-sialyltransferase) in XT/FT knock-down N. benthamiana
plants identiﬁed late targeting sequences as preferential for the
production of naturally occurring, bisected N-glycans (Castilho
et al., 2011).
In a similar approach, enzymes responsible for branched gly-
cans (i.e., tri- and tetraantennary glycans; human α1,3-mannosyl-
β1,4-N-acetylglucosaminyltransferase IVa (GnTIV) and human
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α1,6-mannosyl-β1,6-N-acetylglucosaminyltransferaseV (GnTV))
were tested with different CTS regions (endogenous CTS region,
rat α2,6-sialyltransferase,A. thaliana core α1,3-fucosyltransferase,
A. thaliana β1,2-xyloslytransferase; Castilho et al., 2011; Nagels
et al., 2011, 2012a,b). The fusions with the medial Golgi-targeting
CTS region of, e.g., FT allowed the generation of a high
degree of branched glycans on co-expressed reporter proteins,
whereas the endogenous CTS and the late Golgi CTS from α2,6-
sialyltransferase did not lead to substantial amounts of branched
glycans.
Collectively these results demonstrate that it is not sufﬁcient
to “simply” introduce a foreign glycosylation enzyme into a plant
to obtain a desired glycan structure. Instead, the successful pro-
duction of proteins with human-type N-glycosylation in plants
harbors a large number of challenges and requires knowledge of
glycosylationpathways, enzyme speciﬁcities and related topics, like
subcellular protein transport. Semi-synthetic approaches serve as
useful tools to approach these challenges.
FURTHER CHALLENGES
In recent years, a variety of expression hosts were glyco-engineered
(recently reviewed by, e.g., Jacobs and Callewaert, 2009; Loos and
Steinkellner, 2012) and the ﬁrst productswith enhancedproperties
in animal studies have reached the clinic (Ratner, 2014). Plants,
with their similar-to-human yet more simple N-glycosylation
machinery and their amenability to glyco-engineering have been
on the forefront of this development. Despite substantial achieve-
ments, the advantages of this system have been used only in a
few in vivo studies (Bendandi et al., 2010; Forthal et al., 2010;
Zeitlin et al., 2011, 2013; Hiatt et al., 2014). So far only one plant-
produced product has reached the market, i.e., glucocerebrosidase
to treat Gaucher’s disease. This protein carries terminal mannose
residues, a glycosylation form that confers enhanced efﬁcacies
(Grabowski et al., 2014). Another plant-produced glyco-optimized
protein drug has recently been used to treat patients: ZMapp, an
experimental mAb cocktail against Ebola virus was given to several
individuals during the ongoingEbola epidemic (critically reviewed
by Goodman, 2014). These antibodies had not yet gone through
clinical studies but due to the dire predictions of Ebola virus infec-
tion and lack of other treatment options its application had been
approved by regulatory authorities in several countries.
With the appearance of efﬁcient, transient expression meth-
ods, the rapid, scalable and cost-effective production of high-value
recombinant proteins became possible (Gleba et al., 2014). How-
ever, to realize the full potential of plant biotechnology, advanced,
stably glyco-engineered plant strains in combination with semi-
synthetic approacheswill be needed.Versatile,modular expression
vectors like MoClo (Weber et al., 2011) and GoldenBraid (Sarrion-
Perdigones et al., 2013) allow efﬁcient shufﬂing of domains and
will certainly speed up the generation of constructs. Quick
assembly of multi-gene vectors also simpliﬁes the remodeling
of glycosylation pathways as recently demonstrated (Schneider
et al., 2014). Moreover, new technologies for genome editing, like
CRISPR and TALENs (Lozano-Juste and Cutler, 2014) allow efﬁ-
cient elimination of genes and facilitate metabolic engineering
and reprogramming of biosynthetic processes. These develop-
ments in combination with computer modeling and simulation
approaches that predict protein–glycan interactions will accelerate
the development of drugs with optimized and even new func-
tions. In sum, the currently available gene expression systems
and the new tools offered by synthetic biology create an ideal
environment for establishing a plant-based biomanufacturing
platform that can compete with or even surpass current industry
standards.
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